that Santa Fe Pharmaceutical Industry Laboratory (LIF) will be available, starting June, a pediatric presentation of ibuprofen suspension 2% per 90 milliliters. This will be available for patients from the provincial public health system.
It is new pediatric pharmacological presentations in selected antipyretic and analgesic syrup, which will be added to other people produced at LIF. This version add to ibuprofen 400 milligrams in a tablet.
Local laboratories provide this medicine to the public system at a price of 70% lower than the average price the pharmaceutical manual was updated a month ago.
Provided and used efficiently, this is a tool within the framework of the primary health care strategy, enabling the public health system to resolve most of the problems handled in health centers and hospitals in Santa Fe, in conditions such as colds and minor injuries.
LIF and Rosario National University (UNR) they work at awareness and education for rational administration Ibuprofen analgesic, antipyretic and anti-inflammatory drugs, produced for the entire network of hospitals and health centers in the province.
"We have worked for years with different universities and public and private bodies on recommendations for the use of Ibuprofen and other medicines. In this case of drugs in particular, together with UNR we coordinated several criteria taking into account the warning reports disclosed in last week in European countries and taking into account advice from Drug Information Center (CIM) from the Hospital Pharmacy Treatment Area Centenario de Rosario Pharmacy Services", Declared from the LIF directory.
It is analgesic, antipyretic and anti-inflammatory belongs to the group Nonsteroidal NSAID anti-inflammatory drugs. Blocking story The cyclooxygenase enzyme that produces prostaglandin, substances that are involved in inflammation and pain.
In recent years, health authorities The European Union has regularly reviewed security NSAIDs, including ibuprofen. Reviews carried out in 2005, 2006 and 2012 confirmed that NSAIDs, as a pharmacological group, were associated with a small increase in the risk of thromboembolic events, especially in patients with underlying heart or circulatory disease or with certain cardiovascular risk factors, especially if used in doses high.
that ibuprofen Usually taken in lower doses and for short periods of time. Therefore, there will be no cardiovascular risk in use that is usually done by most patients. In fact, that European Medicines Agency (EMA) stressed that ibuprofen is one of the drugs most often used against pain and inflammation, and has a known safety profile, especially in ordinary doses.
Because of the above, various countries have warned about this risk for pharmacological groups and information about products for all NSAIDs, including ibuprofen. It is recommended that these drugs be used at the lowest effective dose for the shortest period needed to control symptoms.
Recommendations for use
NSAIDs, like all drugs, can cause it side effects, especially gastrointestinal, cardiovascular and kidney.
When choosing NSAIDs, individual patient risk factors, specific safety profiles of each NSAID, and patient personal preferences must be considered.
In general, it is recommended: use NSAIDs with the lowest effective dose and for the shortest possible time; in the case of chronic pain, regularly check the needs and effectiveness of treatment with NSAIDs, which are only symptomatic; and do not combine two NSAIDs. "